|
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) |
|
Jazz Pharmaceuticals Plc
JAZZ's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Jazz Pharmaceuticals Plc's sales fell
by -0.46 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1063
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.5 %
Jazz Pharmaceuticals Plc net loss increased from $-15 millions, to $-93 millions in first quarter of 2025,
• More on JAZZ's Growth
|
|
Jazz Pharmaceuticals Plc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Jazz Pharmaceuticals Plc PEG ratio is at 0.23
Company is currently trading with Price to Cash flow multiple of 15.77 in trailing twelve-month period. |
Company |
14.35 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.62.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on JAZZ's Valuation
|
|
|
|
|
Jazz Pharmaceuticals Plc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Jazz Pharmaceuticals Plc PEG ratio is at 0.23
Company is currently trading with Price to Cash flow multiple of 15.77 in trailing twelve-month period. |
Company |
14.35 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.62.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
Jazz Pharmaceuticals Plc Price to Book Ratio is at 1.58 lower than Industry Avg. of 33.1. and higher than S&P 500 Avg. of 0.01
• More on JAZZ's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com